Navigation Links
Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference
Date:11/24/2014

SAN DIEGO, Nov. 24, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), at The New York Palace Hotel in New York.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is embracing the challenge of improving health by seeking to bring innovative medicines targeting G protein-coupled receptors to patients. Arena's internally discovered drug, BELVIQ® (lorcaserin HCl), is approved in the United States, and Arena is focused on discovering, developing and commercializing additional drugs to address unmet medical needs. Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland. For more information, visit Arena's website at www.arenapharm.com.

Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ® is a registered trademark of Arena Pharmaceuticals GmbH.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about embracing the challenge of improving health; seeking to bring innovative medicines to patients; and Arena's focus, plans, goals, strategy, expectations, research and development programs, and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to commercializing drugs, including regulatory, manufacturing, supply and marketing issues and the availability and use of BELVIQ; cash and revenues generated from BELVIQ, including the impact of competition; Arena's revenues will be based in part on estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding estimates or accounting policies may result in changes to Arena's guidance or previously reported results; the timing and outcome of regulatory review is uncertain, and BELVIQ may not be approved for marketing when expected or ever in combination with another drug, for another indication or using a different formulation or in any other territory for any indication; regulatory decisions in one territory may impact other regulatory decisions and Arena's business prospects; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative arrangements; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development may not meet regulatory requirements or otherwise be sufficient for (or Arena or a collaborator may not pursue) further research and development, regulatory review or approval or continued marketing; Arena's ability to obtain and defend patents; the timing, success and cost of Arena's research and development; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo PartnersCraig M. Audet, Ph.D., Senior Vice President,

David Schull, PresidentOperations & Head of Global Regulatory Affairs

david.schull@russopartnersllc.comcaudet@arenapharm.com

 858.717.2310858.453.7200, ext. 1612 www.arenapharm.com
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference
2. Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation
3. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2014 Financial Results
4. Arena Pharmaceuticals Announces Third Quarter 2014 Conference Call and Webcast on Monday, November 3
5. Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners
6. Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at the American College of Clinical Pharmacy Annual Meeting
7. Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Arena Pharmaceuticals APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension
10. Arena Solutions And SiliconExpert Partner To Reduce Supply Chain Risk
11. Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2019)... (PRWEB) , ... March 20, 2019 , ... ... presentations for its Health IT + Clinical Leadership + Pharmacy Conference, held May ... ,     Terry Bradshaw, Co-Host and Analyst for Fox NFL Sunday and NFL Legend; ...
(Date:3/20/2019)... , ... March 20, 2019 , ... According to ... have higher rates of eye diseases such as cataract, glaucoma and age-related macular ... changes in vision related to pregnancy and menopause. , Prevent Blindness has designated April ...
(Date:3/20/2019)... , ... March 20, 2019 , ... Nike Volleyball ... be directed by Rick Swan, the head volleyball coach at Colorado College. , This ... means that players from the Rocky Mountain area now have an opportunity to train ...
Breaking Medicine Technology:
(Date:3/20/2019)... ... March 20, 2019 , ... People ... is within. , George Goodheart ... Highly Sensitive Person (HSP): A Mini-Encyclopedia of Ways to Develop and Deepen Wonder-full ...
(Date:3/20/2019)... ... 20, 2019 , ... Vera Whole Health , a national leader in ... on-site clinics keep employees healthy and drive down the total cost of care. This ... of adopting on-site clinics. , The Vera white paper covers several topics including:, ...
(Date:3/20/2019)... ... March 20, 2019 , ... ... newly designed website as an improved online resource for ABFM Diplomates. The new ... easy to navigate. , The new website features a responsive design, providing functional ...
(Date:3/20/2019)... , ... March 20, 2019 , ... ... sales growth of 41 percent from 2017 to 2018. In total, sales generated ... , “Our sales and marketing teams delivered significant accomplishments and milestones in 2018. ...
(Date:3/20/2019)... WALNUT CREEK, Calif. (PRWEB) , ... March 20, ... ... solution for the healthcare industry, announced today the launch of its mSource® Predictive ... giving customers the most complete insights. It gives purchased services teams the control ...
Breaking Medicine News(10 mins):